One-Year Clinical and Real-World Outcomes with the TENEO Excimer

In this episode, Drs. Waring and Chu share clinical insights and real-world experience from the first year of using the Teneo 317 excimer laser for correcting myopia and myopic astigmatism. As the first excimer platform to receive FDA approval in over 15 years, the Teneo 317 introduces modern performance to U.S. practices with its compact design, fast ablation speed, and intuitive user interface. The conversation covers key findings from the FDA clinical trial and early post-market use, including exceptional visual acuity outcomes, improved night vision, and high levels of patient satisfaction.

Sponsored by Bausch + Lomb©2025 Bausch + Lomb  TEN.0014.USA.25